donafenib + toripalimab

Donafenib + toripalimab is an experimental combination therapy evaluated for the treatment of hepatocellular carcinoma (HCC), primarily in the unresectable or high-risk post-surgical setting. Donafenib is a small molecule multikinase inhibitor that targets receptor tyrosine kinases involved in tumor cell proliferation and angiogenesis, such as the vascular endothelial growth factor receptor (VEGFR), and is structurally related to sorafenib but designed for improved safety and efficacy. Toripalimab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses by blocking the interaction between PD-1 and its ligands (PD-L1/PD-L2) on tumor cells. The combination aims to leverage both targeted antineoplastic effects and potentiation of immune-mediated tumor destruction. Clinical studies indicate that this regimen can improve objective response rate, disease control rate, progression-free survival, and overall survival in advanced or high-risk HCC populations, with a manageable safety profile in phase 1/2 settings, either as a doublet or as part of triple-therapy with transarterial chemoembolization (TACE)[1][2][3][4][5].

Other names

toripalimab and donafenib combination